Ossica (Ibandronate Sodium Hydrate)

Ibandronate Sodium Hydrate, the active ingredient in Ossica, is a bisphosphonate presented as an intravenous solution for intravenous use. It is indicated for the prevention and treatment of osteoporosis in postmenopausal women and for men at high risk of fracture. The drug works by reducing bone resorption, helping maintain bone density and lower fracture risk.

GNH USA supplies Ossica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ossica (ibandronate sodium hydrate) is used in the management of osteoporosis, a condition characterized by reduced bone mass and increased fracture risk. - Postmenopausal osteoporosis: reduces the risk of vertebral and non‑vertebral fractures. - Male osteoporosis at high risk of fracture: improves bone mineral density and lowers fracture incidence. - Osteoporosis prevention: administered to reduce bone loss in individuals at risk of developing osteoporosis.

Common Side Effects: - Acute phase reaction: fever, chills, myalgia, and headache occurring within 24‑48 hours after infusion. - Nausea or vomiting. - Transient flu‑like symptoms. - Injection site discomfort or erythema. - Arthralgia or joint stiffness. - Elevated serum creatinine (mild).

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Severe hypocalcemia. - Acute renal failure or significant decline in renal function. - Anaphylactic or severe hypersensitivity reactions. - Atrial fibrillation or other serious cardiac events.

Before initiating therapy, consider the following precautions: - Assess renal function: avoid use if creatinine clearance is <30 mL/min. - Monitor serum calcium: correct hypocalcemia before infusion. - Ensure adequate vitamin D and calcium intake to support bone health. - Review concomitant nephrotoxic medications and adjust as needed. - Use with caution in patients with a history of cardiac arrhythmia. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Ibandronate sodium hydrate may interact with several agents:

Major Interactions (Avoid): - Concurrent intravenous bisphosphonates: increased risk of renal toxicity. - High‑dose intravenous contrast agents: may exacerbate renal impairment. - Severe renal impairment (creatinine clearance <30 mL/min): contraindicated.

Moderate Interactions (Monitor Closely): - Calcium, magnesium, or antacid supplements given simultaneously: may reduce drug efficacy; separate administration by at least 4 hours. - Atrial fibrillation‑prone patients: monitor cardiac rhythm during therapy. - Hypocalcemia‑inducing drugs (e.g., loop diuretics): monitor serum calcium levels.